MAP2K1 (MEK1) mutations define a distinct subset of lung adenocarcinoma associated with smoking

Clinical Cancer Research

Volumn 21, Issue 8, 2015, Pages 1935-1943

  Arcila, Maria E ^a   Drilon, Alexander ^a   Sylvester, Brooke E ^a   Lovly, Christine M ^b   Borsu, Laetitia ^a   Reva, Boris ^a,c   Kris, Mark G ^a   Solit, David B ^a   Ladanyi, Marc ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PROTEIN KINASE B;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COHORT ANALYSIS; COMPUTER MODEL; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA DAMAGE; DRUG SENSITIVITY; FEMALE; GENDER; HUMAN; HUMAN CELL; HUMAN TISSUE; INFORMATION RETRIEVAL; LUNG ADENOCARCINOMA; MALE; NUCLEIC ACID BASE SUBSTITUTION; OVERALL SURVIVAL; PRIORITY JOURNAL; RACE; SIGNAL TRANSDUCTION; SMOKING; SOMATIC MUTATION; TREATMENT OUTCOME; ADENOCARCINOMA; ADVERSE EFFECTS; ALLELE; CELL LINE; CHEMISTRY; DNA MUTATIONAL ANALYSIS; EXON; GENE FREQUENCY; GENETICS; GENOTYPE; LUNG NEOPLASMS; METABOLISM; METASTASIS; MIDDLE AGED; MOLECULAR MODEL; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; PROTEIN CONFORMATION; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ALLELES; CELL LINE; DNA MUTATIONAL ANALYSIS; EXONS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MAP KINASE KINASE 1; MIDDLE AGED; MODELS, MOLECULAR; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTEIN CONFORMATION; SMOKING;

EID: 84927633689     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2124     Document Type: Article

References (34)

1. Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol 2008;21 Suppl 2: S16-22.
2. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008;14: 5731-4.
3. Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J Clin Oncol 2011;29: 2046-51.
4. Marks JL, Gong Y, Chitale D, Golas B, McLellan MD, Kasai Y, et al. Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res 2008;68: 5524-8.
5. Derijard B, Raingeaud J, Barrett T, Wu IH, Han J, Ulevitch RJ, et al. Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 1995;267: 682-5.
6. Bromberg-White JL, Andersen NJ, Duesbery NS. MEK genomics in development and disease. Brief Funct Genomics 2012;11: 300-10.
7. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994;77: 841-52.
8. Mansour SJ, Candia JM, Gloor KK, Ahn NG. Constitutively active mitogenactivated protein kinase kinase 1 (MAPKK1) and MAPKK2 mediate similar transcriptional and morphological responses. Cell Growth Differ 1996;7: 243-50.
9. Mansour SJ, Matten WT, Hermann AS, Candia JM, Rong S, Fukasawa K, et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 1994;265: 966-70.
10. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, et al. Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 2006;311: 1287-90.
11. Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M, Fujii Y. MEK1 and AKT2 mutations in Japanese lung cancer. J Thorac Oncol 2010;5: 597-600.
12. Choi YL, Soda M, Ueno T, Hamada T, Haruta H, Yamato A, et al. Oncogenic MAP2K1 mutations in human epithelial tumors. Carcinogenesis 2012;33: 956-61.
13. Murugan AK, Dong J, Xie J, Xing M. MEK1 mutations, but not ERK2 mutations, occur inmelanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle 2009;8: 2122-4.
14. Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, et al. Dissecting therapeutic resistance to RAF inhibition inmelanoma by tumor genomic profiling. J Clin Oncol 2011;29: 3085-96.
15. Arcila M, Lau C, Nafa K, Ladanyi M. Detection of KRAS and BRAFmutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping. J Mol Diagn 2011;13: 64-73.
16. Dias-Santagata D, Akhavanfard S, David SS, Vernovsky K, Kuhlmann G, Boisvert SL, et al. Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2010;2: 146-58.
17. Su Z, Dias-Santagata D, Duke M, Hutchinson K, Lin YL, Borger DR, et al. A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small cell lung cancer. J Mol Diagn 2011;13: 74-84.
18. Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, et al. Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 2008;68: 9375-83.
19. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2: 401-4.
20. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013;6: pl1.
21. Seshagiri S, Stawiski EW, Durinck S, Modrusan Z, Storm EE, Conboy CB, et al. Recurrent R-spondin fusions in colon cancer. Nature 2012;488: 660-4.
22. Zhou JX, Yang H, Deng Q, Gu X, He P, Lin Y, et al. Oncogenic driver mutations in patients with non-small cell lung cancer at various clinical stages. Ann Oncol 2013;24: 1319-25.
23. Waterfall JJ, Arons E, Walker RL, Pineda M, Roth L, Killian JK, et al. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nat Genet 2014;46: 8-10.
24. Imielinski M, Berger AH, Hammerman PS, Hernandez B, Pugh TJ, Hodis E, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 2012;150: 1107-20.
25. Fischmann TO, Smith CK, Mayhood TW, Myers JE, Reichert P, Mannarino A, et al. Crystal structures of MEK1 binary and ternary complexes with nucleotides and inhibitors. Biochemistry 2009;48: 2661-74.
26. Estep AL, Palmer C, McCormick F, Rauen KA. Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy. PLoS ONE 2007;2: e1279.
27. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, et al. A landscape of driver mutations in melanoma. Cell 2012;150: 251-63.
28. Ahrendt SA, Decker PA, Alawi EA, Zhu Yr YR, Sanchez-Cespedes M, Yang SC, et al. Cigarette smoking is strongly associated with mutation of the Kras gene in patients with primary adenocarcinoma of the lung. Cancer 2001;92: 1525-30.
29. Dogan S, Shen R, Ang DC, Johnson ML, D'Angelo SP, Paik PK, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res 2012;18: 6169-77.
30. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst 1999;91: 1194-210.
31. Hainaut P, Pfeifer GP. Patterns of p53 G->T transversions in lung cancers reflect the primary mutagenic signature of DNA-damage by tobacco smoke. Carcinogenesis 2001;22: 367-74.
32. Nikolaev SI, Rimoldi D, Iseli C, Valsesia A, Robyr D, Gehrig C, et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 2012;44: 133-9.
33. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009;106: 20411-6.
34. Shi H, Moriceau G, Kong X, Koya RC, Nazarian R, Pupo GM, et al. Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discov 2012;2: 414-24.